Cellyan Biotechnology Co., Ltd has announced significant changes in its leadership structure, which could have implications for its strategic direction and governance.

On November 10, 2026, Mr. Lap Sun Wong resigned as Chairman of the Board and as a director of Cellyan Biotechnology. His resignation leaves the company without a chairperson, as the position remains vacant until the board resolves otherwise. Mr. Wong stated that his departure was not due to any disagreements regarding the company’s operations or policies.

Additionally, Mr. Zhao Letao, an independent director, also resigned on the same day. He ceased to serve as a member of the audit committee, the compensation committee, and the nominating and corporate governance committee. Like Mr. Wong, Mr. Zhao clarified that his resignation was not the result of any disagreements with the company.

The Board expressed gratitude for the contributions of both Mr. Wong and Mr. Zhao during their tenures.

In response to these departures, the company has made new appointments. Ms. Shu Liu, who has been serving as the Chief Financial Officer since October 2025, was appointed as an executive director effective immediately. Her background in financial management and compliance is expected to support the company’s financial operations.

On November 11, 2026, Mr. Xiaohu Quan was appointed as an independent director, taking over the roles previously held by Mr. Zhao. Mr. Quan brings extensive experience in cross-border supply chain operations, having previously worked at Huawei Technologies Co., Ltd.

Following these changes, the Board now consists of five directors, including two executive directors and three independent directors. The current composition reflects a shift in governance, with Ms. Liu and Mr. Quan stepping into significant roles.

In another noteworthy update, the company announced a name change for its controlling shareholder, Ms. Liying Wang, who is now known as Aylin Ada. This change does not affect any rights or obligations related to her shareholding.

The impact of these leadership changes on Cellyan's operations remains to be seen. The company operates in the wholesale drugs sector, which is characterized by intense competition and regulatory scrutiny. Observers will be keen to see how the new board composition influences the company's strategic direction and market positioning.

As of now, the company has not indicated any immediate next steps following these changes. The leadership transitions may lead to further filings or announcements in the near future.

Details were not available in the SEC filing.